Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00018668 |
Motor slowing is a hallmark, clinical sign in mental illness. Slowness can be related to a specific disease process, as in negative schizophrenia or depression or it can be the result of medications used to treat forms of mental illness. Prior research has lead to a novel instrumental approach for distinguishing subtypes of motor slowing - one type related to cognitive processes and another related to parkinsonism. The purpose of this study is to test whether new medications used to treat schizophrenia improve the cognitive or parkinsonian components of motor slowing. Patients will be studied in the laboratory before and 8-weeks after starting a new antipsychotic. The n of this study = 60 patients. The results of this study will improve our understanding of the complex interactions between cognitive processing and motor behavior in patients with psychotic illnesses and how drugs work to treat these problems.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Risperidone Drug: Olanzapine Drug: Quetiapine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Psychopharmacologic Aspects of Motor Slowing in Schizophrenia |
Ages Eligible for Study: | 21 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Schizophrenia diagnosis currently treated with conventional antipsychotic willing to be switched to an atypical antipsychotic.
Study ID Numbers: | MHBS-041-00S |
Study First Received: | July 3, 2001 |
Last Updated: | January 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00018668 History of Changes |
Health Authority: | United States: Federal Government |
Antipsychotics schizophrenia motor retardation bradykinesia |
Neurotransmitter Agents Tranquilizing Agents Olanzapine Risperidone Psychotropic Drugs Antiemetics Central Nervous System Depressants Antipsychotic Agents Serotonin Uptake Inhibitors Serotonin |
Bradykinesia Schizophrenia Quetiapine Dopamine Mental Disorders Dopamine Agents Psychotic Disorders Peripheral Nervous System Agents Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Olanzapine Psychotropic Drugs Antiemetics Schizophrenia Serotonin Antagonists Mental Disorders Therapeutic Uses Schizophrenia and Disorders with Psychotic Features Tranquilizing Agents |
Gastrointestinal Agents Risperidone Central Nervous System Depressants Dopamine Antagonists Antipsychotic Agents Serotonin Uptake Inhibitors Pharmacologic Actions Quetiapine Serotonin Agents Autonomic Agents Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |